特利加压素联合白蛋白治疗肝肾综合征24例分析

陈思; 孙长宇; 张致淏; 王莹莹

doi:10.3969/j.issn.1001-5256.2014.08.021

特利加压素联合白蛋白治疗肝肾综合征24例分析

DOI: 10.3969/j.issn.1001-5256.2014.08.021

郑州大学第一附属医院感染科

详细信息

中图分类号: R575.3;R692
计量
- 文章访问数: 2546
- HTML全文浏览量: 9
- PDF下载量: 501
- 被引次数: 0
出版历程
- 收稿日期: 2013-09-22
- 出版日期: 2014-08-20

Therapeutic effect of terlipressin combined with albumin in 24 patients with hepatorenal syndrome

Department of Infectious Diseases, The First Affiliated Hospital, Zhengzhou University

摘要

摘要:
目的观察特利加压素联合白蛋白治疗肝肾综合征的疗效。方法回顾性分析2011年5月-2013年8月本院收治的46例肝肾综合征患者,分为2组,对照组22例,治疗组24例,在常规治疗的基础上,对照组给予白蛋白,治疗组给予特利加压素联合白蛋白,观察患者临床症状、尿量、血肌酐、尿素氮、腹水及转归情况。2组间比较用t检验,率的比较采用χ2检验。结果治疗组患者临床症状均得到改善,对照组改善不明显,治疗组患者尿量由（758.5±284.9）ml/24 h增加至（2277.1±704.8）ml/24 h,血肌酐水平由（234.2±87.2）μmol/L下降至（126.8±62.2）μmol/L,尿素氮水平由（18.1±6.4）mmol/L下降至（10.3±4.5）mmol/L,体质量由（68.1±3.9）kg下降至（64.6±3.9）kg,腹围由（95.0±5.1）cm减少至（90.8±4.9）cm,其治疗前后差异有统计学意义（P<0.01）。治疗组治疗后与对照组治疗后比较,差异有统计学意义（P<0.05）。对照组患者治疗前后尿量、血肌酐、尿素氮、体质量及腹围水平无明显变化（p>0.05...
- 肝肾综合征 /
- 血管收缩药 /
- 白蛋白类
Abstract:
Objective To observe the therapeutic effect of terlipressin combined with albumin in management of patients with hepatorenal syndrome.Methods A retrospective study enrolling 46 patients with hepatorenal syndrome from May 2011 to August 2013 was conducted, in which 22 patients were allocated to control group, and 24 patients to treatment group.In addition to conventional treatment, albumin was used in control group, and the patients in treatment group were treated with terlipressin plus albumin.Clinical symptoms, urine volume, serum creatinine, urea nitrogen, ascites, and prognosis were observed in the study.The Student's t test was used for comparison between the two groups, and the chi- square test was used for comparison of rates.Results The treatment group showed significant improvements in clinical symptoms, while the control group did not.In treatment group, urine volume (ml /24 h) increased from (758.5 ± 284.9) to (2277.1 ±704.8) (P<0.01) ;serum creatinine level (μmol/L) dropped from (234.2 ±87.2) to (126.8 ±62.2) (P <0.01) ;urea nitrogen level (mmol /L) dropped from (18.1 ± 6.4) to (10.3 ± 4.5) (P < 0.01) ;body weight (kg) dropped from (68.1 ± 3.9) to (64.6± 3.9) (P < 0.01) ;abdominal circumference (cm) dropped from (95.0 ± 5.1) to (90.8 ± 4.9) (P < 0.01) .However, the control group showed no significant changes in urine volume, serum creatinine, urea nitrogen, body weight, and abdominal circumference after treatment (P >0.05) .There were significant differences in these indices between the two groups after treatment (P < 0.05) .Significant differences in remission rate and survival rate were observed between the control group and treatment group (P < 0.05) .Conclusion A combination of terlipressin and albumin has favorable therapeutic effect on hepatorenal syndrome and improves the prognosis of patients with hepatorenal syndrome.
- hepatorenal syndrome /
- vasoconstrictor agents /
- albumins

HTML全文

参考文献(11)

[1]BOYER TD, SANYAL AJ, GARCIA-TSAO G, et al.Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J].Liver Transpl, 2011, 17 (11) :1328-1332.

[2]WEN Y, WANG DL, LIU P.Activated protein kinase C alpha participates in the decreased glomerular filtration rate in hepatorenal syndrome induced by tumor necrosis factor alpha[J].J Med Res, 2013, 42 (3) :120-123. (in Chinese) 闻颖, 王冬蕾, 刘沛.蛋白激酶Cα激活参与肿瘤坏死因子α引起的肝肾综合征肾小球滤过率下降[J].医学研究杂志, 2013, 42 (3) :120-123.

[3]SALERNO F, GERBES A, GINS P, et al.Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis[J].Gut, 2007, 56 (9) :1310-1318.

[4]KISER TH, MACLAREN R, FISH DN, et al.Treatment of hepatorenal syndrome[J].Pharmacotherapy, 2009, 29 (10) :1196-1211.

[5]WANG JY.Clinical advances on hepatorenal syndrome research[J].Chin J Hepatol, 2011, 19 (3) :161-162. (in Chinese) 王吉耀.重视对肝肾综合征的临床研究[J].中华肝脏病杂志, 2011, 19 (3) :161-162.

[6]SHANG J, CAO Q.Diagnosis of hepatorenal syndrome[J].Chin J Hepatol, 2011, 19 (3) :165-166. (in Chinese) 尚佳, 曹青.肝肾综合征的诊断[J].中华肝脏病杂志, 2011, 19 (3) :165-166.

[7]ZHANG LL.Pathogenesis of hepatorenal syndrome[J].Chin J Hepatol, 2011, 19 (3) :163-164. (in Chinese) 张伦理.肝肾综合征的发病机制[J].中华肝脏病杂志, 2011, 19 (3) :163-164.

[8]WANG JY, DOU XG.Prevention of risk factors and treatment of hepatorenal syndrome[J].Chin J Pract Intern Med, 2013, 33 (9) :687-689. (in Chinese) 王静艳, 窦晓光.肝肾综合征发生的危险因素及防治[J].中国实用内科杂志, 2013, 33 (9) :687-689.

[9] European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[10]ORTEGA R, GINS P, URIZ J, et al.Terlipressin therapy with and without albumin for patients with hepatorenal syndrome:Results of a prospective, nonrandomized study[J].Hepatology, 2002, 36 (4 Pt 1) :941-948.

[11]TRIANTOS CK, SAMONAKIS D, THALHEIMER U, et al.Terlipressin therapy for renal failure in cirrhosis[J].Eur J Gastroenterol Hepatol, 2010, 22 (4) :481-486.

施引文献

资源附件(0)

访问统计